Kubota, Takuo
Namba, Noriyuki
Tanaka, Hiroyuki
Muroya, Koji
Imanishi, Yasuo
Takeuchi, Yasuhiro
Kanematsu, Masanori
Sun, Wei
Seino, Yoshiki
Ozono, Keiichi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies
https://doi.org/10.1007/s12325-022-02412-x
Documents that mention this clinical trial
Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies
https://doi.org/10.1007/s12325-022-02412-x
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
https://doi.org/10.1136/rmdopen-2022-002676
Funding for this research was provided by:
Kyowa Kirin Pharmaceutical Development
Article History
Received: 28 October 2022
Accepted: 15 December 2022
First Online: 31 January 2023